This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GLPG0259
Description: GLPG0259 targets protein kinase MAPKAPK5 (mitogen-activated protein kinase-activated protein kinase 5, formerly encoded by Galapagos as GT418), which represents a new approach for the treatment of rheumatoid arthritis (RA). GLPG0259 is the first small molecule from Galapagos' target discovery platform to enter the clinic.
Galapagos' internal research indicated that MAPKAPK5 is involved in a signaling pathway that is central to inflammation. GLPG0259 inhibits MAPKAPK5, and demonstrates bone protection and reduced inflammation in a standard RA animal model.
Deal Structure: GLPG0259 is a compound in Galapagos' internal RA program, which is part of an alliance with Johnson & Johnson company, Janssen Pharmaceutica. Jannsen has an option to license the worldwide rights to GLPG0259 for 60 million Euros following a successful Phase IIa trial, with further potential milestones to Galapagos of 776 million Euros and double-digit royalties on global sales.
Partners: Johnson & Johnson
Additional information available to subscribers only: